Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Hyperacute GVHD: risk factors, outcomes, and clinical implications

Rima M. Saliba, Marcos de Lima, Sergio Giralt, Borje Andersson, Issa F. Khouri, Chitra Hosing, Shubhra Ghosh, Joyce Neumann, Yvonne Hsu, Jorge De Jesus, Muzaffar H. Qazilbash, Richard E. Champlin, Daniel R. Couriel

Blood (2006) 109 (7): 2751–2758.

https://doi.org/10.1182/blood-2006-07-034348

Published: 2006

Journal Articles

Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD

Daniel R. Couriel, Chitra Hosing, Rima Saliba, Elizabeth J. Shpall, Paolo Anderlini, Beverly Rhodes, Veronica Smith, Issa Khouri, Sergio Giralt, Marcos de Lima, Yvonne Hsu, Shubhra Ghosh, Joyce Neumann, Borje Andersson, Muzzafar Qazilbash, Sharon Hymes, Stella Kim, Richard Champlin, Michele Donato

Blood (2006) 107 (8): 3074–3080.

https://doi.org/10.1182/blood-2005-09-3907

Published: 2006

Journal Articles

Natural History of AML / MDS Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Using Reduced Intensity (RIC) Preparative Regimens.

Betul Oran, MD, Sergio Giralt, MD, Munir Shahjahan, MD, Athanasios Anagnostopoulos, MD, Daniel Couriel, MD, Partow Kebriaei, MD, Chitra Hosing, MD, Shubhra Ghosh, MD, Ernesto de Meis, MD, Michele Donato, MD, Touch Ativivas, MD, Antonio Carrasco-Yalan, MD, Richard Champlin, MD, Marcos de Lima, MD

Blood (2005) 106 (11): 2019.

https://doi.org/10.1182/blood.V106.11.2019.2019

Published: 2005

Journal Articles

Secondary Malignancy after Allogeneic Stem Cell Transplantation: Incidence and Risk Factors.

Chitra Hosing, MD, Rima M. Saliba, PhD, Marcos De Lima, MD, Sergio Giralt, MD, Shubhra Ghosh, MD, Yvonne Hsu, Paolo Anderlini, MD, Sharon R. Hymes, MD, Borje Andersson, MD, Issa F. Khouri, MD, Richard Champlin, MD, Daniel Couriel, MD

Blood (2005) 106 (11): 1123.

https://doi.org/10.1182/blood.V106.11.1123.1123

Published: 2005

Journal Articles

Outcomes of Older Patients with Myeloid Leukemias Treated with Myeloablative Intravenous Busulfan-Based Conditioning Regimens and Allogeneic Blood or Marrow Transplantation.

Marcos de Lima, Daniel Couriel, Shubhra Ghosh, Roy B. Jones, Elizabeth J. Shpall, Sergio Giralt, Chitra Hosing, Partow Kebriaei, Richard Champlin, Borje S. Andersson

Blood (2005) 106 (11): 660.

https://doi.org/10.1182/blood.V106.11.660.660

Published: 2005

Journal Articles

Clinical, Prognostic and Therapeutic Implications in the Diagnosis of Grade I Acute Graft-Versus-Host Disease.

Rima M. Saliba, PhD, Marcos de Lima, MD, Chitra Hosing, MD, Issa F. Khouri, MD, Sergio Giralt, MD, Paolo Anderlini, MD, Shubhra Ghosh, MD, Kerry Mickler, RN, Cindy Ippoliti, PHARMD, Zuraima Caldera, MD, Yvonne Hsu, PAC, Joyce Neumann, APN, Richard Champlin, MD, Daniel R. Couriel, MD

Blood (2005) 106 (11): 1799.

https://doi.org/10.1182/blood.V106.11.1799.1799

Published: 2005

Journal Articles

Sequential Treatment with Reduced Intensity Allogeneic Stem Cell Transplantation and Imatinib for Chronic Myelogenous Leukemia (CML.

Richard Champlin, M.D., Shubhra Ghosh, M.D., Gloria McCormick, R.N., Borje Andersson, M.D., Ph.D., Marcos de Lima, M.D., Paolo Anderlini, M.D., Muzaffar Qazilbash, M.D., Sergio Giralt, M.D., Jorge Cortes, M.D.

Blood (2004) 104 (11): 812.

https://doi.org/10.1182/blood.V104.11.812.812

Published: 2004

Journal Articles

Hyperacute Graft-Versus-Host Disease: Analysis of Risk Factors, Clinical Manifestations and Outcomes.

Daniel R. Couriel, MD, Rima Saliba, PhD, Marcos J. de Lima, MD, Chitra Hosing, MD, Borje Andersson, MD, Jorge De Jesus, RN, Kerry Mickler, RN, Yvonne Hsu, PA, Elizabeth J. Shpall, MD, Shubhra Ghosh, MD, Richard Champlin, MD

Blood (2004) 104 (11): 734.

https://doi.org/10.1182/blood.V104.11.734.734

Published: 2004

NARROW

Hyperacute GVHD: risk factors, outcomes, and clinical implications

Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD

Natural History of AML / MDS Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Using Reduced Intensity (RIC) Preparative Regimens.

Secondary Malignancy after Allogeneic Stem Cell Transplantation: Incidence and Risk Factors.

Outcomes of Older Patients with Myeloid Leukemias Treated with Myeloablative Intravenous Busulfan-Based Conditioning Regimens and Allogeneic Blood or Marrow Transplantation.

Clinical, Prognostic and Therapeutic Implications in the Diagnosis of Grade I Acute Graft-Versus-Host Disease.

Sequential Treatment with Reduced Intensity Allogeneic Stem Cell Transplantation and Imatinib for Chronic Myelogenous Leukemia (CML.

Hyperacute Graft-Versus-Host Disease: Analysis of Risk Factors, Clinical Manifestations and Outcomes.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only